Page 25 - AN-3-3

Advanced Neurology Alzheimer’s and Parkinson’s disease rodent models

disease in experimental models. J Biochem Mol Toxicol. and cellular mechanisms of rapid-acting antidepressants
2020;34(2):e22429. ketamine and scopolamine. Curr Neuropharmacol.
doi: 10.1002/jbt.22429 2017;15(1):11-20.
121. Hethey C, Hartung N, Wangorsch G, Weisser K, Huisinga W. doi: 10.2174/1570159X14666160309114549
Physiology-based toxicokinetic modelling of aluminium in 124. Bajo R, Pusil S, López ME, et al. Scopolamine effects on
rat and man. Arch Toxicol. 2021;95(9):2977-3000. functional brain connectivity: A pharmacological model of
doi: 10.1007/s00204-021-03107-y Alzheimer’s disease. Sci Rep. 2015;5(1):9748.
122. Praticò D, Uryu K, Sung S, Tang S, Trojanowski JQ, Lee VMY. doi: 10.1038/srep09748
Aluminum modulates brain amyloidosis through oxidative 125. Chen WN, Yeong KY. Scopolamine, a toxin-induced
stress in APP transgenic mice. FASEB J. 2002;16(9):1138-1140. experimental model, used for research in Alzheimer’s
doi: 10.1096/fj.02-0012fje disease. CNS Neurol Disord Drug Targets. 2020;19(2):85-93.
123. Wohleb ES, Gerhard D, Thomas A, Duman RS. Molecular doi: 10.2174/1871527319666200214104331

Volume 3 Issue 3 (2024) 19 doi: 10.36922/an.2903